Aurinia Pharmaceuticals Inc. (AUPH)

Over the past six months, Aurinia's stock has been impacted by several events. The company announced its Q4 and full-year 2025 financial results, reporting accelerating growth for LUPKYNIS. A management transition occurred, with Kevin Tang appointed as the new CEO. Aurinia announced a definitive merger agreement to acquire Kezar Life Sciences, Inc. Aurinia reported its Q3 2025 financial results. A conference call was held to discuss positive results from a Phase 1 study of Aritinercept (AUR200).

Based on the available information, there is no explicit mention of demand seasonality for Aurinia Pharmaceuticals' products and services. The company's financial reports indicate consistent growth in LUPKYNIS sales throughout the year, rather than seasonal fluctuations.

Aurinia Pharmaceuticals, Inc. is a biopharmaceutical company focused on therapies for autoimmune diseases with unmet medical needs. Their primary product is LUPKYNIS (voclosporin), an FDA-approved oral therapy for adult patients with active lupus nephritis. LUPKYNIS functions as an immunosuppressant. The company is also developing aritinercept (AUR200) for other autoimmune diseases.

Aurinia Pharmaceuticals Inc. is headquartered in Edmonton, Alberta, Canada, with a presence in North America. They sell LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and to Otsuka Pharmaceutical Co., Ltd. for the European and Japanese markets.

Aurinia Pharmaceuticals focuses on delivering therapies for autoimmune diseases with high unmet medical needs. Aurinia's reputation has been positively influenced by the continued strong performance and accelerating growth of LUPKYNIS. The update to the American College of Rheumatology lupus nephritis treatment guidelines has also contributed to positive sentiment. The recent management transition has been viewed positively, and the advancement of its pipeline with aritinercept also contributes to its reputation.

Aurinia Pharmaceuticals Inc. stock is owned by a mix of institutional shareholders, insiders, and retail investors. Major institutional owners include Tang Capital Management LLC, BlackRock, Inc., and NEA Management Company, LLC. Kevin Tang is the largest individual shareholder.